We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+35.45%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.39B
AUM Growth
+$291M
Cap. Flow
+$36.6M
Cap. Flow %
2.63%
Top 10 Hldgs %
62%
Holding
63
New
10
Increased
3
Reduced
21
Closed
9

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$139M
2
GTH
Genetron Holdings Limited ADS
GTH
+$85.7M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$24.9M
4
IMVT icon
Immunovant
IMVT
+$17.1M
5
KURA icon
Kura Oncology
KURA
+$15.1M

Top Sells

Rank Stock Value
1
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$37.8M
2
KDMN
Kadmon Holdings, Inc.
KDMN
+$32.2M
3
ASND icon
Ascendis Pharma A/S
ASND
+$28.2M
4
LITS
Lite Strategy Inc
LITS
+$26.4M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.39%
2 Financials 8.49%
3 Materials 3.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
26
DELISTED
Akero Therapeutics
AKRO
$14.7M 1.06%
591,169
-217,078
-27% -$4.96M
SAGE
27
DELISTED
Sage Therapeutics
SAGE
$14.3M 1.02%
+343,179
New +$12.5M
CALT
28
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$13.5M 0.96%
+580,000
New +$11.5M
QTTB icon
29
Q32 Bio
QTTB
$462M
$13.3M 0.95%
48,650
-7,381
-13% -$1.97M
KDNY
30
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.8M 0.85%
1,023,712
– –
LRMR icon
31
Larimar Therapeutics
LRMR
$401M
$10.3M 0.74%
+799,662
New +$9.31M
ZLAB icon
32
Zai Lab
ZLAB
$2.06B
$10M 0.72%
122,107
-100,000
-45% -$6.77M
IGMS
33
DELISTED
IGM Biosciences
IGMS
$8.72M 0.63%
119,480
-80,146
-40% -$4.87M
MTNB icon
34
Matinas BioPharma
MTNB
$1.91M
$8.72M 0.63%
225,586
– –
KALA icon
35
KALA BIO
KALA
$14.5M
$8.27M 0.59%
315
– –
AUPH icon
36
Aurinia Pharmaceuticals
AUPH
$1.88B
$8.14M 0.58%
500,732
– –
VSTM icon
37
Verastem
VSTM
$499M
$7.98M 0.57%
386,628
-291,667
-43% -$7.72M
ORTX
38
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$7.95M 0.57%
132,574
-30,149
-19% -$2.76M
CBAY
39
DELISTED
Cymabay Therapeutics
CBAY
$7.29M 0.52%
2,089,356
+1,011,889
+94% +$2.92M
VRNA
40
DELISTED
Verona Pharma
VRNA
$6.99M 0.5%
1,492,951
– –
RNAC icon
41
Cartesian Therapeutics
RNAC
$227M
$6.41M 0.46%
75,193
-186,357
-71% -$16.9M
BDTX icon
42
Black Diamond Therapeutics
BDTX
$97.4M
$6.34M 0.45%
150,349
-101,770
-40% -$3.75M
YARW
43
Yarrow Bioscience, Inc. Common Stock
YARW
$22.9M
$6.3M 0.45%
1,012
-56
-5% -$379K
RVMD icon
44
Revolution Medicines
RVMD
$38.9B
$6.3M 0.45%
199,518
– –
TCDA
45
DELISTED
Tricida, Inc. Common Stock
TCDA
$4.8M 0.34%
174,764
-349,526
-67% -$9.52M
LITS
46
Lite Strategy Inc
LITS
$33.3M
$4.47M 0.32%
54,104
-435,117
-89% -$26.4M
TECX
47
Tectonic Therapeutic
TECX
$524M
$4.43M 0.32%
21,135
-38,678
-65% -$7.97M
CNST
48
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$4.22M 0.3%
140,298
– –
GLMD icon
49
Galmed Pharmaceuticals
GLMD
$4.78M
$4.11M 0.29%
4,778
– –
ATRC icon
50
AtriCure
ATRC
$1.99B
$2.9M 0.21%
64,573
– –
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
LWIC
Leith Wheeler Investment Counsel Vancouver, British Columbia, Canada $1.21B AUM 12.04% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return

Vivo Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Vivo Capital held 63 positions worth $1.39B, up 26% from $1.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Vivo Capital's Q2 2020 filing shows 10 new, 3 increased, 21 reduced and 9 closed positions. Its largest new stake was Legend Biotech: 3,555,007 shares worth $151M. The largest sale was Forty Seven, Inc. Common Stock, an estimated $37.8M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Financials and Materials.

  • Vivo Capital's largest Q2 2020 buy was Legend Biotech: 3,555,007 shares worth $151M.
  • Vivo Capital added most to Amyris Inc. in Q2 2020, an estimated $12.3M increase.
  • Vivo Capital's biggest Q2 2020 reduction was Kadmon Holdings, Inc., cutting an estimated $32.2M.
  • Vivo Capital fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $37.8M.
  • Vivo Capital's ten largest holdings make up 62% of its $1.39B portfolio in Q2 2020.
  • Vivo Capital opened 10 new positions and closed 9 in Q2 2020.
  • Vivo Capital's portfolio value rose 26% quarter-over-quarter to $1.39B.

Based on Vivo Capital's 13F filing for Q2 2020, filed 14 Aug 2020.